Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells

Nutrition and Cancer

Volumn 55, Issue 2, 2006, Pages 185-194

  Reddy, Sudha ^a   Rishi, Arun K ^a   Xu, Hu ^a   Levi, Edi ^a   Sarkar, Fazlul H ^a   Majumdar, Adhip P N ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR RELATED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCASPASE 3; PROTEIN BAD; PROTEIN INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TURMERIC; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CURCUMA; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYROSINE;

CURCUMA LONGA;

EID: 33750850587     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5502_10     Document Type: Article

References (40)

1. McCarty MF: Targeting multiple signaling pathway as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integ Cancer Ther 3, 349-380, 2004.
2. Candena DL and Gill GN: Receptor tyrosine kinases. FESEB J 6, 2332-2337, 1992.
3. Glenney JR: Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases. Biochim Biophys Acta 1134, 113-127, 1992.
4. Joensuu HJ, Roberts PJ, Sarlomo-Rikala M, Anderson LC, Tervahartiala P, et al.: Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 344, 1052-56, 2000.
5. Allen LF, Lenehan PF, Eiseman IA, Elliot WL, and Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29(Suppl 11), 11-21, 2002.
6. Kapitanovic S, Radosavic S, Kapitanovic M, Andelinovic S, Ferencic Z, et al.: The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103-1113, 1997.
7. Yu Y, Rishi A, Turner J, Liu D, Black E, et al.: Cloning of a novel EGFR related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol 280, C1083-C1089, 2001.
8. Xu H, Yu Y, Marciniak DJ, Rishi AK, Sarkar FH, et al.: Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 4, 435-442, 2005.
9. Majumdar APN: Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. Future Oncol 1, 235-246, 2005.
10. Marciniak DJ, Moragoda L, Mohammad R, Yu Y, Nagothu KK, et al.: Epidermal growth factor receptor related protein (ERRP): a potential therapeutic agent for colorectal cancer. Gastroenterology 124, 1337-1347, 2003.
11. Levi E, Mohammad R, Kodali U, Marciniak D, Reddy S, et al.: EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. Anticancer Res 24, 2885-2892, 2004.
12. Zhang Y, Banerjee S, Wang Z-W, Marciniak DJ, Majumdar APN, et al.: Epidermal growth factor receptor-related protein (ERRP) inhibits cell growth and induces apoptosis of BxPC-3 pancreatic cancer cells. Cancer Res 65, 3877-3882, 2005.
13. Zhang Y, Banerjee S, Wang Z, Xu H, Zhang L, et al.: Anti-cellular and anti-tumor activity of EGFR-related protein is mediated by inactivation of erbB receptors and NF-κB in pancreatic cancer. Cancer Res 66, 1025-1032, 2006.
14. McCarty MF: Targeting multiple signaling pathways as strategy for managing prostate cancer: multifocal signal modulation therapy. Integ Cancer Ther 3, 349-380, 2004.
15. Hanif R, Qiao L, Shiff SJ, and Rigas B: Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 130, 576-584, 1997.
16. Chauhan DP: Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 8, 1695-1706, 2002.
17. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, and Conney AH: Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 13, 2183-2186, 1992.
18. Rao CV, Simi B, and Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced omithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 14, 2219-2225, 1993.
19. Rao CV, Rivenson, Simi B, and Reddy BS: Chemoprevention of colon Carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55, 259-266, 1995.
20. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, et al.: Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidem Biomark Prev 11, 535-540, 2002.
21. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847-6854, 2004.
22. Siwak DR, Shishodia S, Aggarwal BB, and Kurzrock R: Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of Ikappa-B kinase and nuclear factor kappa-B activity and independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104, 879-890, 2005.
23. Chen A and Xu J: Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 288, G447-G456, 2005.
24. Liu JP, Baker J, Perkins AS, Robertson EJ, and Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (IGF-1) and type 1 IGF receptor (IGFR). Cell 75, 59-72, 1993.
25. Khandwala HM, McCutcheon IE, Flyvbjerg A, and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21, 215-244, 2000.
26. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 95, 127-137, 2003.
27. Bustin SA and Jenkins PJ: The growth hormone-insulin-like growth factor-1 axis and colorectal cancer. Trends Mol Med 7, 447-454, 2001.
28. Moghal N and Sternberg PW: Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 11, 190-196, 1999.
29. Xiao Z-Q, Li J, and Majumdar APN: Regulation of TGF-α-induced activation of AP-1 in the aging gastric mucosa. Am J Physiol Gastrointest Liver Physiol 285, G396-G403, 2003.
30. Datta SR, Brunet A, and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13, 2905-2927, 1999.
31. Downward J: PI 3-kinase and cell survival. Sem Cell Dev Biol 15, 177-182, 2004.
32. Marciniak DJ, Rishi AK, Sarkar FH, and Majumdar APN: Epidermal growth factor receptor-related peptide inhibits growth pf PC-3 prostate cancer cells. Mol Cancer Ther 3, 1615-1621, 2004.
33. Kane LP, Shapiro VS, Stokoe D, and Weiss A: Induction of NF-kappaB by Akt/PKB kinase. Curr Biol 9, 601-604, 1999.
34. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, et al.: NF-kappaB activation by tumor necrosis factor requires he Akt serine-threonine kinase. Nature 401, 82-85, 1999.
35. Ciariello F: Epidermal growth factor receptor inhibitors in cancer treatment. FutureOncol 1, 221-234, 2005.
36. Hakam A, Yeatman TJ, Liu L, Mora L, Marcet G, et al.: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30, 1128-1133, 1999.
37. Adachi A, CT Lee, Coffee K, Yamagata N, JE Ohm, et al.: Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 123, 1191-1204, 2002.
38. Shimizu M, Deguchi A, Hara Y, Hisataka M, and Weinstein IB: EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Comm 334, 947-953, 2005.
39. Kelly RG, Nally K, Shanahan E, and O'Connell J: Type I insulin-like growth factor receptor expression on colorectal adenocarcinoma cell lines is decreased in response to the chemopreventive agent N-acetyl-L-cysteine. Ann NY Acad Sci 973, 555-558, 2002.
40. Downward J: PI-3 kinase, Akt and cell survival. Cell Dev Biol 15, 177-182, 2004.